Clinical Efficacy of Clostridium Butyricum Dual Live Bacteria Powder Combined with Double-Sided Blue Light Therapy in the Treatment of Neonatal Hyperbilirubinemia
HUO Zhifang, ZHOU Chuan, SONG Huanqing, LI Jingjing, FENG Xiaoxia
The Department of Neonatology, the Second Affiliated Hospital of Zhengzhou University,Zhengzhou Henan 450000
Abstract：【Objective】 To explore the clinical efficacy of Clostridium Butyricum Dual Live Bacteria Powder combined with double-sided blue light therapy in the treatment of neonatal hyperbilirubinemia. 【Methods】 The clinical data of 107 neonates with hyperbilirubinemia admitted to our hospital from February 2020 to February 2023 were retrospectively analyzed. According to different clinical treatment methods, the neonates were divided into the observation group (n=54) and the control group (n=53). Neonates in the control group received routine treatment and double-sided blue light therapy, while those in the observation group received Clostridium Butyricum Dual Live Bacteria Powder treatment on the basis of the control group. The clinical efficacy, laboratory indicators [total bilirubin (TBiL), procalcitonin (PCT), apolipoprotein M (APOM), C-reactive protein (CRP), CD4+, CD8+, CD4+/CD8+, as well as immunoglobulins (IgG, IgA, IgM)], and the incidence of adverse reactions were compared between the two groups. 【Results】 After treatment, the serum TBiL level of neonates in both groups was significantly lower than that before treatment, and the observation group was lower than the control group, with a statistically significant difference (P<0.05). The total effective rate of the observation group was 88.89% (48/54), which was significantly higher than 66.04% (35/53) of the control group, with a statistically significant difference (χ2=8.027, P<0.05). After treatment, the serum CRP, APOM and PCT levels in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). After treatment, IgG, IgA, IgM, CD4+ and CD4+/CD8+ of neonates in both groups were significantly higher than those before treatment, and CD8+ was lower than that before treatment; moreover, IgG, IgA, IgM, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, and CD8+ was lower than that in the control group, with statistically significant differences (P<0.05). The incidence of adverse reactions in the observation group was 3.70% (2/54), which was significantly lower than 18.87% (10/53) in the control group, with a statistically significant difference (P<0.05). 【Conclusion】 It is suggested that Clostridium Butyricum Dual Live Bacteria Powder combined with double-sided blue light therapy has a good clinical efficacy in the treatment of neonatal hyperbilirubinemia, which can significantly reduce the serum TBiL level, improve immune function indicators, alleviate inflammatory response, and has high safety.
霍志芳, 周川, 宋焕清, 李晶晶, 冯晓霞. 酪酸梭菌二联活菌散联合双面蓝光治疗新生儿高胆红素血症的临床疗效[J]. 医学临床研究, 2026, 43(2): 242-245.
HUO Zhifang, ZHOU Chuan, SONG Huanqing, LI Jingjing, FENG Xiaoxia. Clinical Efficacy of Clostridium Butyricum Dual Live Bacteria Powder Combined with Double-Sided Blue Light Therapy in the Treatment of Neonatal Hyperbilirubinemia. JOURNAL OF CLINICAL RESEARCH, 2026, 43(2): 242-245.
2026, Vol. 43 
